Profile data is unavailable for this security.
About the company
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
- Revenue in NOK (TTM)0.00
- Net income in NOK-179.27m
- Incorporated2011
- Employees23.00
- LocationUltimovacs ASAUllernchausseen 64OSLO 0379NorwayNOR
- Websitehttps://ultimovacs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptonic Medical AB | 40.23m | -46.62m | 36.76m | 37.00 | -- | 0.1917 | -- | 0.9138 | -0.025 | -0.025 | 0.0222 | 0.0323 | 0.4185 | 1.42 | 5.49 | 1,055,432.00 | -48.49 | -46.02 | -61.53 | -60.85 | 44.34 | 54.26 | -115.88 | -139.38 | 0.5002 | -140.41 | 0.2084 | -- | -14.93 | 149.65 | -15.55 | -- | 27.15 | -- |
| Fluicell AB | 1.34m | -27.98m | 38.49m | 11.00 | -- | 1.73 | -- | 28.81 | -0.1493 | -0.1493 | 0.0055 | 0.045 | 0.0525 | 0.5265 | 1.98 | 76,294.12 | -109.94 | -87.55 | -141.87 | -126.02 | -17.66 | 72.97 | -2,094.37 | -650.23 | 3.83 | -695.51 | 0.00 | -- | 2.68 | 22.18 | -22.90 | -- | -- | -- |
| Double Bond Phrmcutcl Intrntnl AB (publ) | 1.24m | -17.25m | 38.70m | 10.00 | -- | 10.10 | -- | 31.30 | -0.18 | -0.18 | 0.0125 | 0.0351 | 0.0949 | -- | 21.10 | 120,004.00 | -132.48 | -80.90 | -176.94 | -106.45 | -344.65 | -1,073.66 | -1,395.47 | -1,360.03 | 1.12 | -1.36 | 0.00 | -- | 10.25 | 135.07 | -14.36 | -- | -- | -- |
| Respiratorius AB (publ) | 1.39m | -7.53m | 38.76m | -- | -- | 0.9465 | -- | 27.94 | -0.0229 | -0.0229 | 0.0042 | 0.078 | 0.0461 | -- | -- | -- | -24.98 | -- | -26.52 | -- | 63.66 | -- | -542.36 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -9.55 | -- |
| Orphazyme A/S | 0.00 | -17.91m | 49.13m | 1.00 | -- | 1.95 | -- | -- | -325.75 | -325.75 | 0.00 | 455.65 | 0.00 | -- | -- | 0.00 | -42.26 | -76.08 | -50.77 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Combigene AB | 1.97m | -37.63m | 51.40m | 10.00 | -- | 0.5269 | -- | 26.07 | -1.84 | -1.84 | 0.0967 | 4.78 | 0.0161 | -- | 3.71 | 239,265.00 | -30.66 | -13.00 | -32.33 | -14.58 | -- | -- | -1,908.16 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Nidhogg Resources Holding AB (publ) | 32.97k | -4.34m | 55.73m | 3.00 | -- | 59.38 | -- | 1,690.42 | -0.0021 | -0.0021 | 0.00005 | 0.0005 | 0.0087 | -- | 0.0128 | 10,666.67 | -114.92 | -70.56 | -204.32 | -82.81 | -25,093.75 | -- | -13,156.25 | -- | -- | -- | -- | -- | -- | -- | 77.06 | -- | -- | -- |
| ViroGates A/S | 8.32m | -20.60m | 58.66m | 10.00 | -- | 4.01 | -- | 7.05 | -5.78 | -5.78 | 1.18 | 1.45 | 0.3331 | 0.3869 | 6.80 | 530,700.00 | -82.42 | -46.58 | -89.49 | -52.09 | 69.49 | 77.91 | -247.47 | -238.01 | 8.60 | -19.26 | 0.3626 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| Modus Therapeutics Holding AB | 0.00 | -15.46m | 61.64m | 2.00 | -- | 6.08 | -- | -- | -0.5898 | -0.5898 | 0.00 | 0.2738 | 0.00 | -- | -- | 0.00 | -165.57 | -141.06 | -- | -278.44 | -- | -- | -- | -- | -- | -18.39 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
| Ultimovacs ASA | 0.00 | -179.27m | 63.03m | 23.00 | -- | 0.2899 | -- | -- | -5.21 | -5.21 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -51.97 | -28.80 | -57.15 | -31.12 | -- | -- | -- | -- | -- | -114.19 | 0.0137 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Abera Bioscience AB | 0.00 | -7.86m | 64.37m | 6.00 | -- | 7.10 | -- | -- | -0.5213 | -0.5213 | 0.00 | 0.5733 | 0.00 | -- | -- | 0.00 | -73.37 | -79.42 | -98.59 | -96.10 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.74 | -- | -- | -- |
| PCI Biotech Holding ASA | 6.00m | -16.00m | 66.74m | 7.00 | -- | 2.09 | -- | 11.13 | -0.4287 | -0.4287 | 0.1607 | 0.8548 | 0.1334 | -- | 0.9365 | 857,000.00 | -35.59 | -36.44 | -40.42 | -40.14 | -- | -- | -266.74 | -1,055.43 | -- | -- | 0.0147 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Chosa Oncology AB | 5.15k | -8.84m | 78.93m | -- | -- | 3.54 | -- | 15,323.94 | -0.1745 | -0.1745 | 0.00009 | 0.3054 | 0.0002 | -- | 0.0009 | -- | -28.72 | -51.96 | -31.51 | -61.92 | -- | -- | -171,540.00 | -708.47 | -- | -28.22 | 0.00 | -- | -98.21 | -- | 28.33 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 1.87m | -36.95m | 83.22m | 12.00 | -- | 1.62 | -- | 44.61 | -0.2614 | -0.2614 | 0.0106 | 0.1436 | 0.0386 | -- | 2.43 | 139,307.70 | -76.46 | -20.19 | -86.74 | -20.97 | -97.96 | -- | -1,980.40 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Sprint Bioscience AB | 87.58m | 15.16m | 84.15m | 36.00 | 5.55 | 4.37 | 5.28 | 0.9609 | 0.2108 | 0.2108 | 1.22 | 0.2677 | 2.38 | -- | 13.18 | 3,036,214.00 | 41.28 | -71.22 | 128.58 | -113.71 | 76.51 | 62.75 | 17.31 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| Dextech Medical AB | 0.00 | -4.85m | 89.50m | 1.00 | -- | 2.93 | -- | -- | -0.2546 | -0.2546 | 0.00 | 1.60 | 0.00 | -- | -- | -- | -14.35 | -23.30 | -14.73 | -23.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.52 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Ultimovacs ASA's reporting currency: Norwegian Krone NOK
7.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nordea Investment Management AB (Norway)as of 31 Jul 2024 | 699.84k | 2.04% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 436.38k | 1.27% |
| Folketrygdfondetas of 31 Dec 2023 | 343.47k | 1.00% |
| Equinor Asset Management ASAas of 31 Dec 2023 | 322.96k | 0.94% |
| Sissener ASas of 31 Dec 2023 | 300.00k | 0.87% |
| Danske Invest Asset Management ASas of 30 Aug 2024 | 246.03k | 0.72% |
| Storebrand Asset Management ASas of 31 Aug 2024 | 159.39k | 0.46% |
| DNB Asset Management ASas of 31 Jul 2024 | 156.84k | 0.46% |
| Alfred Berg Kapitalforvaltning ASas of 30 Aug 2024 | 56.09k | 0.16% |
| Parametric Portfolio Associates LLCas of 31 Jul 2024 | 1.73k | 0.01% |
More ▼
Data from 31 Dec 2023 - 31 Aug 2024Source: FactSet Research Systems Inc.
